Ποια είναι η τιμή για Impact Therap-b (7630)

Η τιμή για Impact Therap-b (7630) είναι $1.85

Ποια είναι η κεφαλαιοποίηση αγοράς για Impact Therap-b (7630)

Η κεφαλαιοποίηση αγοράς για Impact Therap-b (7630) είναι $510.85M

Impact Therap-b (7630) Τιμή και Κεφαλαιοποίηση Αγοράς

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

Η τιμή για 7630	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$19,060.58 $510.85M	NVDA	$5.264T	+1,030,305.62%
$17,023.42 $510.85M	AAPL	$4.701T	+920,177.90%
$15,125.65 $510.85M	GOOG	$4.177T	+817,585.33%
$13,822.89 $510.85M	MSFT	$3.817T	+747,158.82%
$10,379.07 $510.85M	AMZN	$2.866T	+560,987.35%

Η τιμή για 7630

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$19,060.58 $510.85M